Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib
Author(s) -
Tadaaki Yamada,
Koushiro Ohtsubo,
Kouji Izumi,
Shinji Takeuchi,
Hisatsugu Mouri,
Kaname Yamashita,
Kazuo Yasumoto,
Peter Ghenev,
Satoshi Kitagawa,
Seiji Yano
Publication year - 2010
Publication title -
international journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.06
H-Index - 62
eISSN - 1437-7772
pISSN - 1341-9625
DOI - 10.1007/s10147-010-0104-3
Subject(s) - medicine , sunitinib , bloody , diffuse alveolar hemorrhage , renal cell carcinoma , bronchoalveolar lavage , nephrectomy , lung , bronchoscopy , lung cancer , pathology , radiology , surgical oncology , surgery , kidney
We report the case of a 67-year-old man with metastatic papillary renal cell carcinoma (RCC) who developed bloody sputum after the administration of sunitinib. Chest computed tomography revealed diffuse ground-glass opacity lesions, and bloody bronchoalveolar lavage fluid was obtained by flexible bronchoscopy. The abnormal shadows promptly regressed after withdrawal of sunitinib. In four cycles of sunitinib treatment, he suffered from controllable diffuse alveolar hemorrhage. Finally, he died of respiratory failure 8 months after onset. This is the first case report of diffuse alveolar hemorrhage as an adverse effect of sunitinib in metastatic papillary RCC. Care should be taken with pulmonary hemorrhage in the use of anti-angiogenesis agents in not only squamous cell lung cancer, but also metastatic lung tumors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom